atorvastatin + ezetimibe + bempedoic acid

Althera Pharma is developing an oral fixed-dose small-molecule combination of **atorvastatin, ezetimibe, and bempedoic acid** for hyperlipidemia and cardiovascular risk reduction. The regimen is designed to produce complementary LDL cholesterol lowering through three established mechanisms: atorvastatin inhibits **HMG-CoA reductase** to reduce hepatic cholesterol synthesis, ezetimibe inhibits **Niemann-Pick C1-Like 1** mediated intestinal cholesterol absorption, and bempedoic acid inhibits **ATP citrate lyase**, an enzyme upstream of HMG-CoA reductase in the cholesterol biosynthesis pathway. Based on the provided Althera pipeline context, the product is an oral combination in NDA/BLA-stage pipeline planning and has been described in strengths including 180/10/40, 180/10/20, and 180/10/10 mg.

Other names

atorvastatin + ezetimibe + bempedoic acidatorvastatin/ezetimibe/bempedoic acid